广东新会维管植物区系的研究

新会市位于广东省中南部 ,地理位置为北纬 2 2°0 5′4 3″～ 2 2°4 8′2 4″,东经 1 1 2°4 7′0 3″～ 1 1 3°1 5′2 4″,南濒南海 .该地区共有维管植物 1 6 98种 ,隶属于 2 0 9科 81 6属 ,其中蕨类植物 32科 5 4属 82种 ,种子植物 1 78科 76 2属1 6 1 6种 .区系地理学研究表明 :蕨类植物地理成分以热带亚热带分布属居多 ,达 2 6属 ,占蕨类总属数的 4 8.1 3% ,而且是以单种属或少种属占优势 .种子植物地理成分以泛热带、热带亚洲分布占绝对优势 ,全部热带成分已达78.0 9% ;其特征科主要有 :山矾科、冬青科、壳斗科、桑科、金缕梅科、山茶科、樟科、萝摩科、大戟科、蝶形花科、野牡丹科、茜草科等 ;中国特有属杉木属、穗花杉属、石笔木属、四药门花属、马蹄参属、天星藤属、大血藤属、刚毛药花属、台闽苣苔属、酸竹属及广东特有属绣球茜草属、异枝竹属等 .与邻近的香港、惠东古田、鼎湖山和黑石顶的植物区系比较其相似性很高 ,体现出南亚热带地区植物区系成分的过渡性及热带区系的渗透性     

NaCl胁迫对藜麦幼苗生长及生理特性的影响

为探讨盐胁迫下两类不同地区藜麦品种幼苗的耐盐机制,该文利用不同浓度的NaCl溶液,对来自青海省海东市乐都区的'LD-13'(低盐地区)和来自青海省海西州乌兰县的'WL-192'(高盐地区)的2个藜麦品种的种子和幼苗进行盐胁迫处理,研究了种子萌发指标(发芽率、发芽势、发芽指数),生长指标(鲜重、根长、茎长)及生理指标(M...     

不同干预时机下复方嗜酸乳杆菌片联合四联疗法在根除幽门螺杆菌失败补救治疗中的应用

目的探讨不同干预时机下复方嗜酸乳杆菌片联合四联疗法在首次根除幽门螺杆菌(H. pylori)失败患者补救治疗中的作用。方法选择西安市第一医院消化内科90例经标准四联疗法根除H. pylori失败的患者为研究对象,随机分为研究组A(A组)、研究组B(B组)与对照组(C组),各30例。A组患者使用复方嗜酸乳杆菌片联合补救四联疗法治疗。B组患者在补救四联疗法结束后序贯使用复方嗜酸乳杆菌片2周。C组患者单独采用补救四联疗法治疗。比较3组患者临床症状、不良反应发生率及H. pylori根除率。结果A组、B组、C组患者总有效率分别为93.33%(28/30),90.00%(27/30),66.67%(20/30),差异有统计学意义(χ²=9.120,P=0.010)。A组、B组、C组患者总不良反应发生率分别为13.33%(4/30)、16.67%(5/30)、66.67%(20/30),差异有统计学意义(χ²=24.522,P<0.001)。A组、B组、C组患者H. pylori根除率分别为60.00%(18/30)、63.33%(19/30)、33.33%(10/30),差异有统计学意义(χ² =6.502,P=0.039)。A组与B组患者H. pylori根除率相比差异无统计学意义(χ²=0.071,P=0.791)。结论复方嗜酸乳杆菌片联合四联疗法可提高首次四联疗法根除H. pylori失败患者H. pylori根除率,改善患者临床症状,降低总体不良反应发生率,但不同干预时机下复方嗜酸乳杆菌片对H. pylori根除率无明显影响。     

烟粉虱内共生菌16S rDNA的变异与系统发生

对 5年连续饲养在不同种寄主植物上的B型烟粉虱北京种群的内共生菌 1 6SrDNA基因进行了PCR扩增和测序。结合已知序列 ,构建了不同寄主植物烟粉虱初生内共生菌约 1 0 0 0bp的 1 6SrDNA及次生内共生菌约1 2 5 0bp的 1 6SrDNA的分子系统树。结果表明 ,中国北京不同寄主植物的B型烟粉虱内共生菌及世界其它地区烟粉虱内共生菌可能是同一种的不同生态型 ,内共生菌在其宿主分化后进行了选择 ,之后与其宿主长期共同进化、共同适应 ,为宿主对不同生境的适应提供了一定的基础     

通过形成类胚体诱导人羊水多能干细胞向心肌细胞分化

由人羊水中分离羊水多能性干细胞,通过形成类胚体诱导其向心肌细胞分化.取人羊水标本进行体外培养,分离得到人羊水干细胞,已连续传代培养至42代,采用免疫细胞化学、RT-PCR和流式细胞仪技术对羊水干细胞的生物学特性进行检测.取10～15代羊水干细胞,悬浮培养使其形成类胚体,进而向心肌细胞诱导分化.培养的羊水干细胞呈成纤维样,表达部分胚胎干细胞特异标志基因,悬浮培养可形成类胚体.类胚体碱性磷酸酶(AP)检测呈阳性,表达三胚层特异标志基因fgf5、ζ-globin和α-fetoprotein.羊水干细胞形成类胚体后进行诱导,得到α-actin阳性细胞,表达心肌细胞特异标志基因Tbx5、Nkx2.5、GATA4和α-MHC.试验结果表明,从人羊水标本中可分离得到具有胚胎干细胞特性的细胞,经初步检测确定为羊水干细胞,并能通过形成类胚体诱导其向心肌细胞分化.     

Wangella harbinensis gen. nov., sp. nov., a new member of the family Micromonosporaceae

A novel endophytic actinomycete, designated strain NEAU-J3^T, was isolated from soybean root (Glycine max (L.) Merr) and characterized using a polyphasic approach. Phylogenetic analysis based on 16S rRNA gene sequences suggested that strain NEAU-J3^T fell within the family Micromonosporaceae. The strain was observed to form an extensively branched substrate mycelium, which carried non-motile oval spores with a smooth surface. The cell walls of strain NEAU-J3^T were determined to contain meso-diaminopimelic acid and galactose, ribose and glucose were detected as whole-cell sugars. The major menaquinones were determined to be MK-9(H₄) and MK-9(H₆). The phospholipids detected were phosphatidylcholine and phosphatidylethanolamine. The major cellular fatty acids were determined to be C_16:0, C_18:1 ω9c, C_18:0, C_17:0, C_17:1 ω7c, anteiso-C_17:0, C_16:1 ω7c and C_15:0. The DNA G + C content was 62.5 mol%. On the basis of the morphological and chemotaxonomic characteristics, phylogenetic analysis and characteristic patterns of 16S rRNA gene signature nucleotides, strain NEAU-J3^T is considered to represent a novel species of a new genus within the family Micromonosporaceae, for which the name Wangella harbinensis gen. nov., sp. nov. is proposed. The type strain of Wangella harbinensis is strain NEAU-J3^T (=CGMCC 4.7039^T = DSM 45747^T).     

迟眼蕈蚊抗菌肽BhSGAMP-1-S在大肠杆菌中的优化表达及其活性分析(英文)

【目的】BhSGAMP-1 是迟眼蕈蚊唾液腺抗菌肽,为了能够更好的了解其分子特性,我们将其表达、纯化并进行了活性测定。【方法】依据大肠杆菌稀有密码子设计并合成了抗菌肽基因 BhSGAMP-1-S,以 pMAL-c2X 作为表达载体在大肠杆菌 TB1 中进行融合表达,融合蛋白通过麦芽糖亲和层析柱进行纯化,获得的融合蛋白经肠激酶切割后,混合物通过分子筛凝胶层析和反相高效液相色谱来获得单体重组抗菌肽 BhSGAMP-1-S,对获得的抗菌肽进行活性测定。【结果】在最优的表达条件下融合蛋白以可溶的形式表达,100 mL 诱导菌液经多步纯化后可得 0. 38 mg 的重组抗菌肽 BhSGAMP-1-S,抑菌活性测定表明所获得的抗菌肽对部分测试革兰氏阳性细菌、革兰氏阴性细菌和真菌有较强的抑菌活性。【结论】本研究第一次成功的在大肠杆菌中诱导表达了修饰合成的抗菌肽 BhSGAMP-1-S,纯化后的抗菌肽具有很好的抑菌活性,这为进一步研究和应用奠定了基础。     

BRG1 variant rs1122608 on chromosome 19p13.2 confers protection against stroke and regulates expression of pre-mRNA-splicing factor SFRS3

A single nucleotide polymorphism (SNP) rs1122608 on chromosome 19p13.2 and in the BRG1/SMARCA4 gene was previously associated with coronary artery disease (CAD). CAD and ischemic stroke are both associated with atherosclerosis. Thus, we tested the hypothesis that rs1122608 is associated with ischemic stroke. Further studies were used to identify the most likely mechanism by which rs1122608 regulates atherosclerosis. For case–control association studies, two independent Chinese Han GeneID cohorts were used, including a Central cohort with 1,075 cases and 2,685 controls and the Northern cohort with 1,208 cases and 824 controls. eQTL and real-time RT-PCR analyses were used to identify the potential candidate gene(s) affected by rs1122608. The minor allele T of SNP rs1122608 showed significant association with a decreased risk of ischemic stroke in the Central GeneID cohort (adjusted P _adj = 2.1 × 10^?4, OR 0.61). The association was replicated in an independent Northern GeneID cohort (P _adj = 6.00 × 10^?3, OR 0.69). The association became more significant in the combined population (P _adj = 7.86 × 10^?5, OR 0.73). Allele T of SNP rs1122608 also showed significant association with a decreased total cholesterol level (P _adj = 0.013). Allele T of rs1122608 was associated with an increased expression level of SFRS3 encoding an mRNA splicing regulator, but not with the expression of BRG1/SMARCA4 or LDLR (located 36 kb from rs1122608). Increased expression of SFSR3 may decrease IL-1β expression and secretion, resulting in reduced risk of atherosclerosis and stroke. This is the first study that demonstrates that rs1122608 confers protection against ischemic stroke and implicates splicing factor SFSR3 in the disease process.